An open-label, Phase II, platform trial evaluating safety and efficacy of multiple BI 754091 anti-PD-1 based combination regimens in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy
This study is being done in subjects with advanced and/or metastatic solid tumors. The treatment-specific Module A portion of the study will test the combination of the investigational drugs BI 754091 and BI 754111.
- IRB Number: 1904395200 (1381-0009)
- Research Study Identifier: TX10498
- Principal Investigator: Greg Durm, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required